NXE Q1 2026 Earnings Wider Than Expected Loss as Development Continues Passage Bio Q1 2026 Earnings Narrowerthanexpected loss signals disciplined spending VET Q1 2026 Earnings Significant EPS Miss With Flat Market Reaction DAWN Q4 2025 Earnings Miss on EPS as PreRevenue Biotech Invests in Pipeline UCL Q1 2026 Earnings Narrower Loss Surprises Analysts as Shares Dip FSEA Q3 2024 Earnings Modest Profit Amid Narrowing Margins